Previous 10 | Next 10 |
Anebulo Pharmaceuticals (NASDAQ:ANEB): FQ1 GAAP EPS of -$0.07 beats by $0.04. Cash of $19.20M Press Release For further details see: Anebulo Pharmaceuticals EPS beats by $0.04
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending Jun...
Read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors have big meetings with the Federal Reserve and OPEC to track even as earnings reports continue to roll in. The...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today reported that the ...
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that managem...
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the three and 12 months ended June 30, 2021 and rep...
The following slide deck was published by Anebulo Pharmaceuticals, Inc. in conjunction with this event. For further details see: Anebulo Pharmaceuticals (ANEB) Investor Presentation - Slideshow
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the completion of finished product manufacturing of its lead drug ANE...
News, Short Squeeze, Breakout and More Instantly...
Anebulo Pharmaceuticals Inc. Company Name:
ANEB Stock Symbol:
NASDAQ Market:
Anebulo Pharmaceuticals Inc. Website:
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), has been awarded the first tranche of a two year cooperati...
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...